共 414 条
[31]
Romain S(2008)Defining prognosis for women with breast cancer and CNS metastases by HER2 status Ann Oncol Off J Euro Soc Med Oncol/ESMO 19 1242-384
[32]
Tubiana N(2010)Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377-3255
[33]
Beedassy B(2010)Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer J Clin Oncol Off J Am Soc Clin Oncol 28 3248-103
[34]
Martin PM(2004)High incidence of HER-2 positivity in inflammatory breast cancer Breast 13 97-1838
[35]
Serment H(2006)Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol Off J Am Soc Clin Oncol 24 1831-53
[36]
Piana L(2003)Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol Off J Am Soc Clin Oncol 21 46-208
[37]
Hance KW(1989)Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance Int J Cancer J Int du Cancer 43 201-32
[38]
Anderson WF(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-127
[39]
Devesa SS(2010)Effects of guideline adherence in primary breast cancer—a 5-year multi-center cohort study of 3976 patients Breast 19 120-365
[40]
Young HA(2013)Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9,156 patients BMC Cancer 13 487-2646